alexa Revisiting INH: QSAR-based Design Of New Anti-tubercular Compounds
ISSN: 2161-0444

Medicinal Chemistry
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

3rd International Conference on Medicinal Chemistry & Computer Aided Drug Designing
December 08-10, 2014 DoubleTree by Hilton Hotel San Francisco Airport, USA

Filomena Martins
ScientificTracks Abstracts: Med Chem
DOI: 10.4172/2161-0444.S1.011
Tuberculosis (TB) ranks as the second leading cause of death from a single infectious agent, the Mycobacterium tuberculosis (Mtb). WHO reports 8.6 million new TB cases and 1.3 million deaths worldwide in 2012. The emergence of multidrug resistant (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) has reduced considerably the number of available drugs for treatment, making the quest for ?new?, effective and non-toxic drugs a major concern. Despite the significant progresses made in the last ten years in the development of new anti-TB drugs, with several compounds reaching phases 2 and 3 of the clinical pipeline, the truth is that isoniazid (INH), firstly synthesized in 1952, remains one of the most effective drugs to treat TB. Any new compound derived from INH that proves to be active against several forms of tuberculosis, would certainly be less problematical than totally new compounds with unknown long-term effects as those recently introduced in therapeutic combination regimens. In this work we show how a judicious and well-validated QSAR methodology can be used to successfully design new INH-based derivatives with better activitiesthan the parent compound against both susceptible and resistant Mtb strains. Also, some evidences will be presented that question the putative increase in resistance of katG (S315T) towards INH, when compared with wtkatG.
Filomena Martins has obtained her PhD at the University of Lisbon in 1993. She did postdoctoral work with Prof. Michael Abraham at the University College London and Dr. Robert Mitchell at SmithKline Beecham Pharmaceuticals at Welwyn, Hertfordshire, UK. She is currently Assistant Professor at the University of Lisbon where she is responsible for the Structure and Reactivity Group of the Chemistry and Biochemistry Centre. Her present research interests include the development of judicious and well validated quantitative structure-property relationships (QSPRs) to design (and synthesize) new molecules with better biological or physicochemical performance. She has more than 40 publications in the areas of Physical and Medicinal Chemistry.
image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version